HSD17B10 and early-onset autosomal dominant Alzheimer disease: In this study, the first industrial-scale high-throughputscreeningof nearly 350,000 drug-like molecules targeting the enzyme 17β-HSD10,a promising therapeutic target for Alzheimer’s disease andcancers, is presented.